US Patent

US11903918 — Fumarate ester dosage forms with enhanced gastrointestinal tolerability

Method of Use · Assigned to Banner Life Sciences LLC · Expires 2035-02-27 · 9y remaining

Vulnerability score 63/100 Moderate — design-around opportunities exist

What this patent protects

This patent protects methods for treating multiple sclerosis with pharmaceutical compositions containing monomethyl fumarate to reduce gastrointestinal side effects.

USPTO Abstract

Described herein are pharmaceutical compositions comprising one or more fumarate esters and methods for treating multiple sclerosis subjects with the compositions where the incidence of gastrointestinal side effects is reduced compared to treatments comprising dimethyl fumarate (e.g., TECFIDERA®). In particular, described herein are oral pharmaceutical compositions comprising monomethyl fumarate in a liquid vehicle that have reduced gastrointestinal side effects.

Drugs covered by this patent

FDA Patent Use Codes

When a patent is method-of-use, FDA lists it once per applicable indication ("U-code"). Each U-code carves out a specific therapeutic use that generic filers must either license or design around.

CodeDescriptionDrug
U-1384 — monomethyl-fumarate

Patent Metadata

Patent number
US11903918
Jurisdiction
US
Classification
Method of Use
Expires
2035-02-27
Drug substance claim
No
Drug product claim
No
Assignee
Banner Life Sciences LLC
Source
FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.